PUBLISHER: Grand View Research | PRODUCT CODE: 1888546
PUBLISHER: Grand View Research | PRODUCT CODE: 1888546
The global AI in life science analytics market size was estimated at USD 1.94 billion in 2024 and is projected to reach USD 4.84 billion by 2033, growing at a CAGR of 10.64% from 2025 to 2033. The global market is experiencing significant growth driven by advancements in AI and machine learning technologies.
Innovations in AI technologies have transformed the analysis of complex, large-scale biological and clinical data. Advancements such as deep learning, generative AI, and high-performance computing facilitate faster, more accurate drug discovery and personalized medicine development. These innovations have enhanced the analysis of complex and large-scale datasets, thereby improving drug discovery, personalized medicine, and patient care. In addition, increased investments from pharmaceutical companies and government initiatives supporting AI research and development are contributing to market expansion. AI's capabilities in streamlining clinical trials, optimizing supply chain management, and enhancing decision-making processes are further accelerating its adoption within the life sciences industry.
Life sciences industries focus on enhancing health through innovative medical solutions, including drug development, critical disease treatments, and minimally invasive surgical equipment to improve patient outcomes and recovery times. Companies are actively advancing AI innovation in this sector. For example, in October 2023, Fujitsu Limited and RIKEN's HPC- and AI-driven Drug Development Platform Division introduced an AI technology that predicts protein's structural changes from electron microscope images, generating 3D density maps using generative AI.
Government initiatives supporting AI in life sciences vary globally, reflecting diverse strategies to leverage AI for healthcare, biomedical research, and pharmaceutical innovation. These initiatives aim to accelerate technological advancements, foster cross-sector collaboration, and address regulatory and ethical challenges. Notably, the U.S. has made substantial progress with the National Artificial Intelligence Initiative Office (NAIIO), established in early 2021, which coordinates AI research and development across federal agencies, academia, and industry.
Key players in the market are increasingly focused on enhancing their AI-based tools to improve quality and capabilities. In March 2022, Sorcero launched 'Clarity,' a tool designed to offer medical affairs teams an integrated view across all areas of scientific engagement. Utilizing Sorcero's advanced analytics, medical teams can now visualize and track medical content at scale. In addition, in 2022, CloudMedx introduced 'ACO REACH Explorer,' aimed at unifying and visualizing disparate data to enhance health equity and Omni channel patient engagement.
Global AI in Life Science Analytics Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global AI in life science analytics market report based on deployment, component, application, end use, and region.